Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INO
  • CUSIP: N/A
  • Web:
  • Market Cap: $563.92 million
  • Outstanding Shares: 90,227,000
Average Prices:
  • 50 Day Moving Avg: $6.22
  • 200 Day Moving Avg: $6.64
  • 52 Week Range: $5.28 - $9.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.15
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $51.84 million
  • Price / Sales: 10.84
  • Book Value: $1.59 per share
  • Price / Book: 3.92
  • EBITDA: ($70,600,000.00)
  • Net Margins: -153.46%
  • Return on Equity: -63.67%
  • Return on Assets: -46.77%
  • Current Ratio: 3.90%
  • Quick Ratio: 3.90%
  • Average Volume: 1.57 million shs.
  • Beta: 2.76
  • Short Ratio: 4.01

Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals's stock reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.08. The firm earned $20.41 million during the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. Inovio Pharmaceuticals's revenue was up 229.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.26) EPS. View Inovio Pharmaceuticals' Earnings History.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?

10 equities research analysts have issued twelve-month price targets for Inovio Pharmaceuticals' shares. Their predictions range from $10.00 to $40.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $20.20 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.

What are analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inovio has a collaboration agreement with several companies and institutes like big pharma companies Roche, AstraZeneca, and the University of Pennsylvania, which not only lend it their expertise but also provide the required funding for development of its pipeline candidates. Also, the company’s progress with its pipeline is impressive. Nonetheless, the company’s targeted cervical cancer market holds huge untapped potential. The initiation of phase III program on its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. However, due to the early/mid-stage nature of Inovio’s pipeline, the company is highly dependent on VGX-3100, which is concerning. Shares of the company have underperformed the industry so far this year." (10/10/2017)
  • 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:

  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
  • Peter D. Kies, Chief Financial Officer
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer
  • Mark L. Bagarazzi M.D., Chief Medical Officer
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
  • George W. Bickerstaff III, Director
  • David B. Weiner, Director
  • Simon X. Benito, Independent Director
  • Angel Cabrera Ph.D., Independent Director

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $6.23.

MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  305 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $20.20 (224.24% upside)
Consensus Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)
Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)
Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$11.00N/AView Rating Details
10/17/2017HC WainwrightSet Price TargetBuy$13.00N/AView Rating Details
10/6/2017Citigroup Inc.Initiated CoverageBuy$10.00N/AView Rating Details
9/12/2017Maxim GroupReiterated RatingBuy$12.00LowView Rating Details
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies Group LLCReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 17($0.21)($0.13)$16.29 million$20.41 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)
Current Year EPS Consensus Estimate: $-0.88 EPS
Next Year EPS Consensus Estimate: $-1.21 EPS


Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 24.83%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.20View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.00View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)
Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
DateHeadline logoCorporate News Blog - Inovio Initiates Phase-1b/2 Cancer Efficacy Trial - October 19 at 5:31 AM logoInovio Pharmaceuticals, Inc. (INO) Receives Consensus Recommendation of "Hold" from Analysts - October 18 at 11:02 PM logoInovio Initiates Bladder Cancer Study With Roche's Tecentriq - Nasdaq - Nasdaq - October 18 at 1:41 AM logoInovio Initiates Bladder Cancer Study With Roche's Tecentriq - October 18 at 1:41 AM logoInovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 ... - GlobeNewswire (press release) - October 16 at 3:39 PM logoInovio Pharmaceuticals, Inc. (INO) Cut to "Sell" at BidaskClub - October 14 at 8:22 AM logo-$0.22 EPS Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter - October 12 at 4:26 AM logoETFs with exposure to Inovio Pharmaceuticals, Inc. : October 9, 2017 - October 9 at 7:56 PM logoInovio Pharmaceuticals, Inc. (INO) Now Covered by Analysts at Citigroup Inc. - October 7 at 6:06 PM logoInovio Pharma (INO) Says Positive Zika Vaccine Clinical Study Data Published in NEJM - - October 7 at 4:38 AM logoInovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 - October 6 at 11:34 PM logoInovio Pharmaceuticals, Inc. (INO) PT Set at $13.00 by HC Wainwright - October 6 at 9:12 AM logoA Zika Vaccine Shows Signs of Success in an Early Human Trial - Fortune - October 6 at 8:43 AM logoBrainstorm Health: Zika Vaccine, Sanofi/Regeneron Catch a Break, Does Obamacare Still Exist - October 6 at 12:24 AM logoBRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine - October 6 at 12:24 AM logoInovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers - October 6 at 12:23 AM logoZika vaccine shows promise in early human trial - Reuters - October 5 at 8:58 AM logoInovio's Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine - GlobeNewswire (press release) - October 5 at 8:58 AM logoInovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine - October 5 at 8:58 AM logoGLOBAL DNA VACCINE MARKET FORECAST 2017-2025 - October 4 at 5:37 PM logoZika vaccine shows promise in early human trial - October 4 at 5:37 PM logoInovio Pharmaceuticals, Inc. (INO) Receives Average Rating of "Buy" from Analysts - September 23 at 8:50 PM logoInovio Pharmaceuticals, Inc. (INO) Expected to Post Earnings of -$0.22 Per Share - September 23 at 2:26 PM logoInovio Pharmaceuticals' (INO) "Buy" Rating Reiterated at HC Wainwright - September 22 at 5:44 PM logoETF Preview: ETFs, Futures Mixed Following Weekly Jobless Claims, Philly Fed Manufacturing Data - September 21 at 4:07 PM logoInovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection ... - GlobeNewswire (press release) - September 21 at 9:29 AM logoInovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies - September 21 at 9:29 AM logoInovio shares jump 5% premarket after two peer-reviewed paper support its research - September 21 at 9:29 AM logoInovio Pharma (INO) and Its Partners Begin Phase 1/2a Trial to ... - - September 20 at 4:21 PM logoInovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : INO-US : September 20, 2017 - September 20 at 4:21 PM logoBRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection - September 18 at 7:23 PM logoInovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection - September 18 at 7:23 PM logoInovio Pharmaceuticals, Inc. (INO) Rating Reiterated by HC Wainwright - September 17 at 10:58 PM logoInovio Pharmaceuticals, Inc. (INO) Stock Rating Reaffirmed by Maxim Group - September 17 at 10:58 PM logoInovio Pharmaceuticals (INO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 13 at 3:13 AM logoINO-5150 generated antigen specific T cell immune responses in a phase 1b clinical study - September 11 at 8:38 PM logoInovio Pharma Reports Promising Phase 1b Clinical Trial Data Of INO-5150 - September 11 at 8:38 PM logoInovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer - September 11 at 8:38 PM logoInovio Pharmaceuticals, Inc. (INO) Earns Buy Rating from Analysts at Citigroup Inc. - September 10 at 8:16 PM logoSurging Earnings Estimates Signal Good News for Inovio (INO) - September 7 at 8:11 PM logoIs Inovio Pharmaceuticals Stock Poised for a Rebound? - September 6 at 6:25 AM logo$14.04 Million in Sales Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter - September 6 at 3:16 AM logoIs Inovio Pharmaceuticals Stock Poised for a Rebound? - Motley Fool - August 30 at 2:17 AM logoInovio Pharmaceuticals, Inc. (INO) Given Average Recommendation of "Buy" by Analysts - August 29 at 9:14 PM logoFinancial Review: Inovio Pharmaceuticals (INO) and Abeona Therapeutics (ABEO) - August 24 at 10:26 PM logoInovio Pharmaceuticals to Participate in Upcoming Investment Conferences - August 24 at 7:59 AM logoIronwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers - - August 22 at 12:07 AM logoInovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $14.04 Million - August 19 at 1:34 PM logoInovio Pharmaceuticals, Inc. (INO) Short Interest Update - August 12 at 1:44 AM logoInovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat - August 11 at 11:24 PM



Inovio Pharmaceuticals (INO) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.